当前位置: 首页 > 详情页

Stroke-heart syndrome: current progress and future outlook

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Peoples Hosp Suzhou New Dist, Dept Neurol, Suzhou 215129, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, 45 Changchun St, Beijing 100053, Peoples R China [3]Capital Med Univ, Xuanwu Hosp, Beijing Key Lab Hypox Conditioning Translat Med, Beijing 100053, Peoples R China [4]Capital Med Univ, Clin Ctr Combined Heart & Brain Dis, Beijing 100069, Peoples R China [5]Capital Med Univ, Beijing Inst Brain Disorders, Collaborat Innovat Ctr Brain Disorders, Beijing 100069, Peoples R China [6]Capital Med Univ, Xuanwu Hosp, Dept Emergency, 45 Changchun St, Beijing 100053, Peoples R China
出处:
ISSN:

关键词: Remote ischemic conditioning Stroke-heart syndrome Acute ischemic stroke Central autonomic network Cardiac dysfunction

摘要:
Stroke can lead to cardiac complications such as arrhythmia, myocardial injury, and cardiac dysfunction, collectively termed stroke-heart syndrome (SHS). These cardiac alterations typically peak within 72 h of stroke onset and can have long-term effects on cardiac function. Post-stroke cardiac complications seriously affect prognosis and are the second most frequent cause of death in patients with stroke. Although traditional vascular risk factors contribute to SHS, other potential mechanisms indirectly induced by stroke have also been recognized. Accumulating clinical and experimental evidence has emphasized the role of central autonomic network disorders and inflammation as key pathophysiological mechanisms of SHS. Therefore, an assessment of post-stroke cardiac dysautonomia is necessary. Currently, the development of treatment strategies for SHS is a vital but challenging task. Identifying potential key mediators and signaling pathways of SHS is essential for developing therapeutic targets. Therapies targeting pathophysiological mechanisms may be promising. Remote ischemic conditioning exerts protective effects through humoral, nerve, and immune-inflammatory regulatory mechanisms, potentially preventing the development of SHS. In the future, well-designed trials are required to verify its clinical efficacy. This comprehensive review provides valuable insights for future research.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学
JCR分区:
出版当年[2022]版:
Q1 CLINICAL NEUROLOGY
最新[2023]版:
Q1 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Peoples Hosp Suzhou New Dist, Dept Neurol, Suzhou 215129, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, 45 Changchun St, Beijing 100053, Peoples R China
共同第一作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17044 今日访问量:2 总访问量:913 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院